Congestive heart failure drug market to reach $30M by 2017
The market for congestive heart failure (CHF) drug treatments is estimated at $18 billion in 2007, and is expected to reach $30 billion by 2017, according to a new report by Kalorama Information.
The report noted that growth is being driven by three factors: an increased incidence of CHF; the application of innovative technologies in search of targeted therapies, which is creating opportunity for new entrants into this market; and physicians prescribing multi-drug regimens in response to the failure of traditional drugs to treat CHF.
“The future of CHF drug treatments lies in newer technologies such as biotechnology and genomics,” notes Kalorama analyst Kenneth Krul. “The identification of fetal genes associated with CHF, new treatments that address the endothelium and cell therapy to regenerate damaged heart muscle tissue present some promising areas.”
The market for drugs to treat CHF will continue to be dominated by major pharmaceutical companies which supply product lines with broad cardiovascular applications, according to the report.
Kalorama also said that there are, however, many smaller companies focusing primarily on CHF and biotech, and their numbers are growing with the realization that the disease presents a major economic opportunity for which there is currently no adequate answer.
The Kalorama report focuses on the market potential resulting from the application of current and advanced pharmaceutical and biopharmaceutical technology to the development of CHF treatments in the United States, France, Germany, Italy, Spain, United Kingdom and Japan, providing forecasts through 2017.
The report noted that growth is being driven by three factors: an increased incidence of CHF; the application of innovative technologies in search of targeted therapies, which is creating opportunity for new entrants into this market; and physicians prescribing multi-drug regimens in response to the failure of traditional drugs to treat CHF.
“The future of CHF drug treatments lies in newer technologies such as biotechnology and genomics,” notes Kalorama analyst Kenneth Krul. “The identification of fetal genes associated with CHF, new treatments that address the endothelium and cell therapy to regenerate damaged heart muscle tissue present some promising areas.”
The market for drugs to treat CHF will continue to be dominated by major pharmaceutical companies which supply product lines with broad cardiovascular applications, according to the report.
Kalorama also said that there are, however, many smaller companies focusing primarily on CHF and biotech, and their numbers are growing with the realization that the disease presents a major economic opportunity for which there is currently no adequate answer.
The Kalorama report focuses on the market potential resulting from the application of current and advanced pharmaceutical and biopharmaceutical technology to the development of CHF treatments in the United States, France, Germany, Italy, Spain, United Kingdom and Japan, providing forecasts through 2017.